Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

Jun 06 2019

• By Sue Sutter and Joseph Haas

Bio 2019 Notebook for Scrip — Lartruvo's market removal was a signal that the system works, former FDA official says

Related Content

Lilly Shouldn't Return Sales From Now-Withdrawn Lartruvo, Gottlieb Says

Jun 06 2019

A Successful Failure? Lartruvo’s Speedy Withdrawal Sets New Bar For Accelerated Approval Drugs

Apr 25 2019

Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease

Jun 04 2019

Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

Apr 26 2019

‘Regulatory Risk’: A New Factor In Risk/Benefit Equation At US FDA?

Nov 30 2016

Related Companies

Eli Lilly and Company

Parexel International Corp.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Novartis AG

AveXis, Inc.

Sanofi

Ablynx N.V.

Alnylam Pharmaceuticals Inc.

Halozyme Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Genentech, Inc.

Roche Holding AG

Merck & Co., Inc.

AstraZeneca PLC

Additional Topics

Drug Review Review Pathway Deals M & A Commercial Regulation ASCO BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window